Related Experiment Videos

[The clinical evaluation of ceftizoxime suppositories in the pediatric field]

Insights

Ceftizoxime suppository (CZX-S) effectively treats pediatric bacterial infections like bronchitis and UTI. This new rectal antibiotic showed good patient tolerability and clinical outcomes.

Area of Science:

  • Pediatric infectious diseases
  • Pharmacokinetics and drug efficacy
  • Antibiotic therapy

Background:

  • Bacterial infections in children require effective and well-tolerated treatments.
  • Ceftizoxime suppository (CZX-S) is a novel rectal formulation for pediatric use.

Observation:

  • Clinical evaluation of CZX-S in 5 pediatric cases with acute bronchitis, tonsillitis, UTI, and pertussis.
  • Blood levels of CZX ranged from 3.26-23.3 µg/ml within 10-20 minutes post-administration (10.0-26.3 mg/kg dose).
  • Urinary excretion rates within 6 hours were measured (15.2-60.2%).

Findings:

  • Excellent clinical effects were observed in 3 cases, and good effects in 2 cases.
  • One case showed slight elevation in GOT and GPT; no other adverse effects were noted.
  • Patients demonstrated good tolerability to the rectal suppository formulation.

Implications:

  • Ceftizoxime suppository (CZX-S) demonstrates significant utility in treating various pediatric bacterial infections.
  • The favorable pharmacokinetic profile and clinical efficacy suggest CZX-S as a valuable therapeutic option.
  • Good tolerability supports the use of CZX-S in pediatric patients where oral administration may be challenging.

Related Concept Videos